October 21, 2024
3 min watch
Save
VIDEO: Timdarpacept ‘might have legs’ in chronic myelomonocytic leukemia treatment
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Noah Merin, MD, PhD, discusses the results of a study into the use of timdarpacept for chronic myelomonocytic leukemia, presented at ESMO Congress.
Merin, director of the leukemia program at Cedars-Sinai Medical Center, highlighted the study, which examined timdarpacept in combination with azacitidine as a first-line treatment for chronic myelomonocytic leukemia (CMML), and produced what Merin saw as promising results compared with magrolimab in terms of a lower chance of hemolysis.
“This drug might be a better option — this drug might have legs,” Merin said.
Reference:
- Tong H, et al. Abstract 801MO. Presented at European Society for Medical Oncology Congress; Sept. 13-17; Barcelona, Spain.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Merin reported no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.